Nephrology

Advertisement
Charlotte RobinsonERA Congress 2025 | June 4, 2025
Winners of the 2025 ERA Awards and ERA Awards for Young Investigators were recognized at the 62nd ERA Congress.
Victoria SochaEnd-Stage Renal Disease | June 4, 2025
Pain coping skills training demonstrated benefits for patients on maintenance hemodialysis in a randomized clinical trial.
Victoria SochaEnd-Stage Renal Disease | June 3, 2025
Hemodialysis patients reporting shorter sleep or problems sleeping had a higher mortality risk in an observational study.
Victoria SochaChronic Kidney Disease | June 2, 2025
Finerenone had kidney and cardiovascular benefits for patients with CKD even after an acute eGFR change occurred.
Victoria SochaNephrology Times | May 30, 2025
Higher cardiovascular mortality risk was associated with higher CKM syndrome stage, research showed.
Charlotte RobinsonNephrology Times | May 29, 2025
The Annual Global Summit on Kidney Disease Innovations included sessions on rare diseases, human organ alternatives, and more
Victoria SochaChronic Kidney Disease | May 29, 2025
A dual SGLT inhibitor may have ischemic benefits for patients with CKD, T2D, and cardiovascular risks, a study found.
Victoria SochaChronic Kidney Disease | May 28, 2025
An analysis of CKD trials supported 3-year total slope as the primary slope-based outcome in randomized trials.
Victoria SochaNephrology Times | May 27, 2025
Cyclophosphamide-rituximab therapy and minimal use of glucocorticoids in ANCA-associated vasculitis may reduce morbidity.
Victoria SochaADPKD | May 26, 2025
The race of patients with ADPKD affects waitlist experience, allograft quality, and post-transplant outcomes, a study found.
Victoria SochaADPKD | May 23, 2025
A study of real-world data found that tolvaptan reduced long-term kidney function decline in ADPKD.
Victoria SochaAcute Kidney Injury | May 22, 2025
Using serum cystatin C as a biomarker for AKI could prove to be a valuable addition to diagnostic protocols, a study reports.
Charlotte RobinsonNephrology Times | June 3, 2025
In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.
Katie KoskoIgA Nephropathy | May 20, 2025
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Peter Richardson, BMedSci, BM, BS, MRCPAcute Kidney Injury | May 21, 2025
Drs. Peter Richardson and George Wan of Mallinckrodt Pharmaceuticals discussed new data on terlipressin for HRS-AKI.
Charlotte RobinsonIgA Nephropathy | May 20, 2025
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Katie KoskoIgA Nephropathy | May 19, 2025
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
Katie KoskoIgA Nephropathy | May 15, 2025
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Charlotte RobinsonChronic Kidney Disease | May 14, 2025
Researchers fitted a face mask with a breath sensor that may be able to detect the presence of chronic kidney disease.
Freely FilteredADPKD | May 14, 2025
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
Advertisement